Cinpanemab
- Generic Name
- Cinpanemab
- Drug Type
- Biotech
- CAS Number
- 2094516-02-4
- Unique Ingredient Identifier
- W83JGQ40XX
- Background
Cinpanemab is under investigation in clinical trial NCT03318523 (Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease).
Prasinezumab Phase IIb Trial Fails Primary Endpoint, Shows Promise in Parkinson's Subgroup
• Genentech's prasinezumab Phase IIb PADOVA study in early-stage Parkinson's missed its primary endpoint of delaying motor progression.
• A pre-specified analysis showed a more pronounced effect in patients treated with levodopa (HR=0.79), suggesting a potential benefit in this subgroup.
• The investigational monoclonal antibody continues to be well-tolerated, with ongoing open-label extension studies to further explore observed effects.
• Roche plans to present full PADOVA study results at an upcoming medical meeting and will work with health authorities to determine next steps.
UCB's Minzasolmin Fails Phase 2 ORCHESTRA Trial for Early Parkinson's Disease
• UCB's minzasolmin, an oral alpha-synuclein misfolding inhibitor, did not meet primary or secondary endpoints in the Phase 2 ORCHESTRA trial for early Parkinson's.
• The ORCHESTRA study enrolled over 450 patients to assess minzasolmin's efficacy, safety, tolerability, and pharmacokinetics over 12-18 months.
• UCB will terminate the extension phase of the minzasolmin program and shift focus to glovadalen (UCB0022) and UCB7583 for Parkinson's treatment.
• Analysis of disease biomarker data from the ORCHESTRA study is ongoing, with findings to be submitted for publication in a peer-reviewed journal.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath